Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

A case of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis (POIKTMP) with the emphasis on cutaneous histopathological findings.

Kazlouskaya V, Feldman EJ, Jakus J, Heilman E, Glick S.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e443-e445. doi: 10.1111/jdv.14968. Epub 2018 May 1. No abstract available.

PMID:
29578632
2.

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.

Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.

Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15.

3.

Antibody-Based Treatment of Acute Myeloid Leukemia.

Garfin PM, Feldman EJ.

Curr Hematol Malig Rep. 2016 Dec;11(6):545-552. doi: 10.1007/s11899-016-0349-7. Review.

PMID:
27734262
4.

Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014.

Feldman EJ.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S91-3. doi: 10.1016/j.clml.2015.02.031. Review.

PMID:
26297287
5.

Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease.

Dezfoli S, Horton HA, Thepyasuwan N, Berel D, Targan SR, Vasiliauskas EA, Dubinsky M, Shih DQ, Kaur M, McGovern DP, Ippoliti A, Feldman EJ, Melmed GY.

Inflamm Bowel Dis. 2015 Aug;21(8):1754-60. doi: 10.1097/MIB.0000000000000448.

PMID:
25985242
6.

Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.

Roboz GJ, Ritchie EK, Carlin RF, Samuel M, Gale L, Provenzano-Gober JL, Curcio TJ, Feldman EJ, Kligfield PD.

J Clin Oncol. 2014 Nov 20;32(33):3723-8. doi: 10.1200/JCO.2013.51.2913. Epub 2014 Sep 22.

PMID:
25245447
7.

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE.

Cancer. 2015 Jan 15;121(2):234-42. doi: 10.1002/cncr.28974. Epub 2014 Sep 15.

8.

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.

Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F.

Leuk Lymphoma. 2015 Feb;56(2):395-400. doi: 10.3109/10428194.2014.918970.

9.

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ.

Blood. 2014 May 22;123(21):3239-46. doi: 10.1182/blood-2013-12-540971. Epub 2014 Mar 31.

10.

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.

Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. doi: 10.1007/s00280-013-2249-z. Epub 2013 Aug 15.

11.

Septic shock caused by Klebsiella pneumoniae carbapenemase-producing Enterobacter gergoviae in a neutropenic patient with leukemia.

Satlin MJ, Jenkins SG, Chen L, Helfgott D, Feldman EJ, Kreiswirth BN, Schuetz AN.

J Clin Microbiol. 2013 Aug;51(8):2794-6. doi: 10.1128/JCM.00004-13. Epub 2013 Jun 12.

12.

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.

Ritchie EK, Feldman EJ, Christos PJ, Rohan SD, Lagassa CB, Ippoliti C, Scandura JM, Carlson K, Roboz GJ.

Leuk Lymphoma. 2013 Sep;54(9):2003-7. doi: 10.3109/10428194.2012.762093. Epub 2013 Feb 7.

13.

Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies.

Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, Feldman EJ, Roboz GJ, Shore TB, Helfgott DC, Soave R, Kreiswirth BN, Walsh TJ.

Leuk Lymphoma. 2013 Apr;54(4):799-806. doi: 10.3109/10428194.2012.723210. Epub 2012 Sep 14.

PMID:
22916826
14.

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.

Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, Mayer LD, Louie AC, Lancet JE.

Leuk Res. 2012 Oct;36(10):1283-9. doi: 10.1016/j.leukres.2012.07.006. Epub 2012 Jul 26.

PMID:
22840315
15.

Are low-intensity induction strategies better for older patients with acute myeloid leukemia?

Roboz GJ, Wissa U, Ritchie EK, Gergis U, Mayer S, Scandura JM, Christos PJ, Feldman EJ.

Leuk Res. 2012 Apr;36(4):407-12. doi: 10.1016/j.leukres.2011.12.019. Epub 2012 Feb 8.

16.

Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?

Feldman EJ.

Best Pract Res Clin Haematol. 2011 Dec;24(4):523-6. doi: 10.1016/j.beha.2011.09.008. Epub 2011 Nov 2.

PMID:
22127315
17.

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.

Karp JE, Vener TI, Raponi M, Ritchie EK, Smith BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, Carraway HE, Ironside V, Galkin S, Levis MJ, McDevitt MA, Roboz GR, Gocke CD, Derecho C, Palma J, Wang Y, Kaufmann SH, Wright JJ, Garret-Mayer E.

Blood. 2012 Jan 5;119(1):55-63. doi: 10.1182/blood-2011-08-370825. Epub 2011 Oct 14.

18.

Treatment of polycythemia vera with imatinib mesylate.

Silver RT, Bourla MH, Vandris K, Fruchtman S, Spivak JL, Feldman EJ, Salvado AJ.

Leuk Res. 2012 Feb;36(2):156-62. doi: 10.1016/j.leukres.2011.09.001. Epub 2011 Oct 7.

PMID:
21983176
19.

Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation?

Feldman EJ, Gergis U.

Curr Hematol Malig Rep. 2012 Mar;7(1):74-7. doi: 10.1007/s11899-011-0101-2. Review.

PMID:
21979876
20.

Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.

Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, Michelson AD.

J Thromb Haemost. 2011 Nov;9(11):2302-10. doi: 10.1111/j.1538-7836.2011.04506.x.

21.

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

Scandura JM, Roboz GJ, Moh M, Morawa E, Brenet F, Bose JR, Villegas L, Gergis US, Mayer SA, Ippoliti CM, Curcio TJ, Ritchie EK, Feldman EJ.

Blood. 2011 Aug 11;118(6):1472-80. doi: 10.1182/blood-2010-11-320093. Epub 2011 May 25.

22.

Too much ara-C? Not enough daunorubicin?

Feldman EJ.

Blood. 2011 Feb 24;117(8):2299-300. doi: 10.1182/blood-2011-01-328633.

PMID:
21350058
23.

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC.

J Clin Oncol. 2011 Mar 10;29(8):979-85. doi: 10.1200/JCO.2010.30.5961. Epub 2011 Jan 31.

24.

Should patients with low-risk myelodysplastic syndrome be treated earlier in the course of their disease?

Feldman EJ.

Curr Hematol Malig Rep. 2011 Mar;6(1):1-2. doi: 10.1007/s11899-010-0072-8. No abstract available.

PMID:
21161616
25.

Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.

Roboz GJ, Ritchie EK, Curcio T, Samuel M, Provenzano J, Segovia J, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.

Leuk Res. 2011 Apr;35(4):522-5. doi: 10.1016/j.leukres.2010.09.010. Epub 2010 Oct 16.

PMID:
20956016
26.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.

J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23.

27.

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.

Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL.

Leuk Lymphoma. 2009 Aug;50(8):1336-44. doi: 10.1080/10428190903050013.

PMID:
19557623
28.

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann SH.

Blood. 2009 May 14;113(20):4841-52. doi: 10.1182/blood-2008-08-172726. Epub 2008 Dec 24.

29.

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.

Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.

Cancer. 2008 Nov 1;113(9):2504-11. doi: 10.1002/cncr.23855.

30.

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, List A.

Leukemia. 2008 Sep;22(9):1707-11. doi: 10.1038/leu.2008.156. Epub 2008 Jun 12.

PMID:
18548095
31.

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.

Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA.

Leuk Lymphoma. 2008 Jul;49(7):1274-8. doi: 10.1080/10428190802043887.

32.

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP.

Ann Oncol. 2008 Jul;19(7):1327-30. doi: 10.1093/annonc/mdn045. Epub 2008 Mar 17.

PMID:
18349031
33.

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, Löwenberg B, Stone RM, De Porre P, Wang Y, Karp JE.

Blood. 2008 Mar 1;111(5):2589-96. Epub 2007 Dec 26.

PMID:
18160667
34.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF.

Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.

PMID:
17893227
35.

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.

Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, Feldman EJ, Roboz GJ.

Leuk Res. 2007 Jul;31(7):891-7.

PMID:
17560285
36.

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.

Roboz GJ, Bennett JM, Coleman M, Ritchie EK, Furman RR, Rossi A, Jhaveri K, Feldman EJ, Leonard JP.

Leuk Res. 2007 Aug;31(8):1141-4. Epub 2007 May 1.

PMID:
17475326
37.

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ.

J Clin Oncol. 2007 Jan 1;25(1):10-5. Epub 2006 Dec 4.

PMID:
17146106
38.

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE.

Blood. 2007 Feb 15;109(4):1387-94. Epub 2006 Nov 2.

39.

Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.

Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S.

Clin Cancer Res. 2006 Oct 1;12(19):5809-16.

40.
41.

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ.

Leukemia. 2006 Jun;20(6):952-7.

PMID:
16617323
42.

Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells.

Karajannis MA, Vincent L, Direnzo R, Shmelkov SV, Zhang F, Feldman EJ, Bohlen P, Zhu Z, Sun H, Kussie P, Rafii S.

Leukemia. 2006 Jun;20(6):979-86.

PMID:
16598308
43.

Farnesyltransferase inhibitors in myelodysplastic syndrome.

Feldman EJ.

Curr Hematol Malig Rep. 2006 Mar;1(1):20-4. doi: 10.1007/s11899-006-0013-8. Review.

PMID:
20425327
44.

Cyclic Vomiting Syndrome in 41 adults: the illness, the patients, and problems of management.

Fleisher DR, Gornowicz B, Adams K, Burch R, Feldman EJ.

BMC Med. 2005 Dec 21;3:20.

45.

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D.

J Clin Oncol. 2005 Jun 20;23(18):4110-6.

PMID:
15961759
46.

Farnesyltransferase inhibitors in myelodysplastic syndrome.

Feldman EJ.

Curr Hematol Rep. 2005 May;4(3):186-90. Review.

PMID:
15865870
47.

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.

Clin Cancer Res. 2004 Aug 15;10(16):5327-34.

48.

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.

Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM.

Leuk Res. 2003 Dec;27(12):1091-6.

PMID:
12921945
49.

Monoclonal antibody therapy in acute myeloid leukemia.

Feldman EJ.

Curr Hematol Rep. 2003 Jan;2(1):73-7. Review.

PMID:
12901157
50.

Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.

Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA.

Am J Gastroenterol. 2003 May;98(5):1058-63.

PMID:
12809828

Supplemental Content

Loading ...
Support Center